MedTrace Logo

GIP: Glucose-dependent Insulinotropic Peptide

NCT00239707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-11-28

No results posted yet for this study

Summary

The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.

Conditions

Interventions

DRUG

GIP

One-time 20 ng/kg/min infusion over 3 hours

DRUG

Modified GIP

One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl

DRUG

Normal Saline

one-time infusion over 3 hours

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Josephine Egan, MD · Chief, Diabetes Section, National Institute on Aging

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239707 on ClinicalTrials.gov